Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: -2.4%
1M: +2.4%
3M: +0.6%
YTD: +2.0%
1Y: -5.0%
3Y: +9.2%
5Y: -49.0%
$27.73
-0.48 (-1.70%)
Pre-Market: $27.75 (+0.02, +0.07%)
Weekly Expected Move ±14.0%
$20
$24
$28
$32
$36
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress2 trades
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range22.24-46
Volume614,589
Avg Volume1,062,554
Beta0.58
Dividend—
Analyst Ratings
Company Info
CEOBrian Goff
Employees486
SectorHealthcare
IndustryBiotechnology
IPO Date2013-07-24
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139-4169
US
Cambridge, MA 02139-4169
US
617 649 8600
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Latest News
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios (AGIO) Q1 2026 Earnings Call Transcript
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Burns James William | M-Exempt | 8,500 | — | 2026-04-02 |
| Burns James William | S-Sale | 3,280 | $34.71 | 2026-04-02 |
| Burns James William | M-Exempt | 8,500 | — | 2026-04-02 |
| Gheuens Sarah | M-Exempt | 8,500 | — | 2026-04-02 |
| Gheuens Sarah | S-Sale | 2,940 | $34.71 | 2026-04-02 |